Radicava stalls in EU as skeptical regulators demand new ALS trial by Kyle Blankenship Friday, May 31, 2019 Mitsubishi Tanabe’s Radicava touted its FDA approval as a win for ALS patients. But on the clinical data that backed it, the EU wants to see more.
New Mitsubishi Tanabe tool finds ALS care centers for patients by Beth Snyder Bulik Wednesday, May 22, 2019 MTPA, maker of ALS treatment Radicava, has opened up its care locator database to help patients to find healthcare and infusion centers.
Samsung BioLogics, Gardasil and more—FiercePharmaAsia by Angus Liu Friday, November 16, 2018 Samsung BioLogics faces potential delisting; Merck will increase Gardasil supply to China; Chinese officials mulls new regulation for vaccine.
Mitsubishi Tanabe spotlights teen ALS caregivers by Beth Snyder Bulik Wednesday, November 14, 2018 Mitsubishi Tanabe Pharma is looking for ALS stories. Not patient stories, but rather the stories—and art and video creations—of teen caregivers.
FiercePharmaAsia—Zai Lab, Takeda, Fosun and Shanghai Pharma by Angus Liu Friday, August 18, 2017 Zai Lab filed for a $115 million Nasdaq IPO, Takeda formed an R&D deal with Stanford, Fosun and Shanghai Pharma aim to buy a stake in Arbor, and more.
Payers line up to back pricey new ALS med Radicava by Carly Helfand Wednesday, August 16, 2017 How do you get 100% of the payers you approach to cover a pricey new med? Mitsubishi Tanabe’s commercial chief has an idea.
FiercePharmaAsia—Wockhardt, Takeda, Mitsubishi Tanabe by Angus Liu Friday, May 12, 2017 Wockhardt reported a widened Q4 loss, Takeda penned a T-cell platform deal, and the FDA approved Mitsubishi’s ALS drug Radicava.
Mitsubishi Tanabe eyes 2017 U.S. approval for edaravone in ALS by Phil Taylor Thursday, September 1, 2016 Mitsubishi Tanabe is hoping to end a 20-year drought in the U.S. for new ALS medicines.
